Suzuken's Health Creation Business
Suzuken Group's Businesses
Our Business Domain: Health Creation
Creating healthier and better lives…
The Suzuken Group defines its business as health creation.
With the wholesaling of pharmaceuticals at our core, we engage in a wide array of medical and health-related operations including pharmaceutical R&D and manufacturing, support services for manufacturers, operation of pharmacies, and nursing care.
Suzuken Group's Strengths
"Traditional Asset," a relationship of trust with our customers
The Group’s customers include not only medical institutions, pharmacies, and pharmaceutical companies, but also those working in medical and nursing care, patients, and even local residents and communities.
The relationships of trust that we have built thus far with our customers are an important traditional asset we should value above all else.
Medical distribution platform that integrates all elements from manufacturers to patients
By taking responsibility for the whole process of manufacturer distribution and wholesale distribution, we are building a medical distribution platform that integrates all elements from pharmaceutical companies to medical institutions and last-mile delivery.
This distribution model contributes to the improvement of distribution quality and the reduction of social costs, such as the improvement of delivery efficiency and the optimization of distribution inventory, by taking responsibility for the whole process of distribution in accordance with global standards.
Cubixx, a total traceability system using RFID
With the establishment of the healthcare distribution platform, we have the industry-leading track record in the single-company distribution of specialty drugs, which require strict temperature, inventory and security management.
The introduction of the Cubixx System has realized total traceability using digital technologies such as IoT and RFID, thereby contributing to reduction in disposal losses and workloads of medical front lines.
Digital platform connecting various digital healthcare services
As digitalization accelerates in the medical and healthcare fields, we are developing the digital platform COLLABO Portal jointly with health-tech companies and our partner companies utilizing information obtained through our business and existing relationships with our customers.
As a platform connecting people and digital services, COLLABO Portal contributes to solving issues for patients, community healthcare, and the medical and nursing care professionals supporting it.
The Future of the Suzuken Group
Toward a "health creation enterprise" that contributes to all aspects of health creation for patients
Positioning the current period as the third development phase, the Suzuken Group aims to realize a “health creation enterprise” that contributes to “health creation” for patients through the concept of focus on functions combining the functions cultivated in each business and the services of partner companies to provide new value.
Three drivers of growth set forth by Suzuken
-
Digital HealthcareBuilding a healthcare platform
-
Smart LogisticsVisualizing distribution inventory
-
Community-based in-Home HealthcareRealizing a comprehensive support services for in-home medical treatment and nursing care service
Slogan of the New Medium-Term Management Plan
Shareholder Returns
Trends in the dividend per share and the dividend payout ratio
The Suzuken Group promotes management with a strong focus on return on equity (ROE) and strives to enhance capital efficiency while preventing the excessive accumulation of shareholders’ equity. Under this policy, the Company will pay dividends and flexibly conduct share repurchases, using a total payout ratio of 100% as a guideline.
With respect to its dividend policy, the Company will adopt dividend on equity (DOE) as a performance indicator in order to enhance the stability and predictability of dividends. During the period of the Medium-Term Management Plan, the Company intends to increase DOE on a phased basis, setting a target level of approximately 3% in the final fiscal year ending March 31, 2029.